YOLFTbeta
Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc.

PTHS · AMEX · Healthcare / Biotechnology

7.44USD-0.59 (-7.35%)

Price History

Full chart

Market Stats

Previous Close8.03
Open7.87
Day Range7.27 – 8.46
52-Week Range18.19 – 37.50
Volume53.96K
Market Cap84.95M
P/E (TTM)0.00
Forward P/E0.00
EPS-28.63
Dividend Yield0.00%
Beta3.05
50-Day Avg25.64
200-Day Avg25.06

About

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Scott M. Plesha
  • Employees92
  • Headquarters4020 Stirrup Creek Drive, Durham, NC, United States, 27703, USA
  • Websitehttps://pelthos.com

Leadership

  • Mr. Scott M. PleshaCEO, President & Director · b. 1965
  • Mr. Sai Rangarao M.B.A.Chief Commercial Officer · b. 1984
  • Mr. John M. Gay CPACFO, Treasurer & Secretary · b. 1976

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue199.93K000016.80M
Growth (%)--100.00%----
Cost of Revenue----09.37M
Gross Profit199.93K---07.43M
Gross Margin100.00%----44.24%
Operating Expense1.55M---7.57M39.86M
Operating Income-1.35M-839.00K-2.32M-6.86M-7.57M-32.43M
Operating Margin-677.16%-----193.09%
EBITDA-658.91K-595.13K-2.32M-6.86M-7.17M-45.41M
EBITDA Margin-329.56%-----270.37%
Net Income-660.58K-595.39K-2.46M-7.38M-7.96M-43.32M
Net Income Margin-330.40%-----257.93%
R&D138.59K209.05K391.73K2.58M1.18M1.23M
R&D as % of Total Revenue69.32%----7.31%
Interest Expense1.68K253140.43K518.51K786.39K3.01M
Interest Expense % of Total Revenue0.84%----17.93%

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-055.07K96.39K1.37M130.40M
Total Liabilities-3.68M3.76M6.54M4.08M91.52M
Total Equity--3.68M-3.71M-6.44M-2.71M38.88M
Cash-055.07K96.39K513.44K18.02M
Total Debt--540.43K1.27M2.19M34.83M
Net Debt--485.36K1.17M1.67M16.80M

Cash Flow

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.59M-1.57M-981.03K-5.79M-22.59M
Investing Cash Flow-----5.24M
Financing Cash Flow1.59M1.62M1.02M6.21M45.34M
Capital Expenditure000099.00K
Free Cash Flow-1.59M-1.57M-981.03K-5.79M-22.69M
FCF to OCF100.00%100.00%100.00%100.00%100.44%

Earnings

Report DateMay 29, 2024Aug 13, 2024Nov 13, 2024Feb 26, 2025May 28, 2025Aug 13, 2025Nov 13, 2025Mar 19, 2026May 14, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate--2.90-2.300.00--6.26-0.57-4.18-3.58-3.02-2.83
EPS Actual-5.50-3.10-2.90-0.32-3.21-5.38-5.30-2.69-4.66-6.62-
Surprise--6.90%-26.09%--14.06%-829.82%35.65%-30.24%-119.21%-
Timing-After-hoursAfter-hours--After-hoursPre-marketPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap84.95M
Enterprise Value138.96M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.96
Price / Book2.86
EPS-28.63
Book Value-0.404
Revenue (TTM)43.30M
Gross Profit (TTM)32.73M
EBITDA-29.12M
Profit Margin-199.50%
Operating Margin-101.41%
Return on Equity-333.84%
Return on Assets-49.98%
Shares Outstanding3.83M
Shares Float1.42M
Beta3.05
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 2, 20251:10